FIELD: chemistry.
SUBSTANCE: invention relates to novel cocrystals of niflumic acid with isonicotinamide or caffeine, where molar ratio of niflumic acid with isonicotinamide or caffeine constitutes 1:1, and cocrystal of niflumic acid with isonicotinamide has entothermic peak from 152 to 162°C according to the data of measurement by means of differential scanning calorimetry and peaks at 2θ(°) 6.3, 7.4, 12.5, 14.5, 19.2, 23.2, 25.0 by the data of measurement of X-ray radiation difraction on powder, and cocrystal of niflumic acid with caffeine has endothermic peak from 155 to 165°C by the data of measurements by means of differential scanning calorimetry and peaks at 2θ(°) 9.7, 12.0, 13.26, 14.3, 17.0, 18.1, 22.5, 26.2 and 26.9 by the data of measurement of X-ray radiation diffraction on powder.
EFFECT: increase of solubility in water in comparison with indices of niflumic acid solubility in pure form.
12 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CO-CRYSTALLINE FORM OF THEOPHYLLINE WITH DIFLUNISAL OR DICLOFENAC | 2013 |
|
RU2542100C1 |
| CO-CRYSTALLINE FORM OF 2-HYDROXYBENZAMIDE AND 4-AMINOBENZOIC ACID | 2012 |
|
RU2497804C1 |
| CO-CRYSTALLINE FORM OF 2-HYDROXYBENZAMIDE WITH SALICYLIC ACID | 2013 |
|
RU2539350C1 |
| DIFLUNISAL CO-CRYSTALLINE FORM | 2016 |
|
RU2617849C1 |
| CO-CRYSTALLINE FORM OF BICALUTAMIDE | 2012 |
|
RU2510392C1 |
| COCRYSTALLINE FORM OF FENBUFEN | 2012 |
|
RU2521572C1 |
| CO-CRYSTALLINE FORM OF ISONIAZID | 2016 |
|
RU2630957C1 |
| CO-CRYSTALLINE FORM OF 1-[(5-PARA-METHYL-META-CHLORO-PHENYLAMINO)-1,2,4-THIADIAZOL-3-YL]-PROPAN-2-OL | 2019 |
|
RU2721335C1 |
| COCRYSTALLINE FORM OF 1-[5-(4-CHLOROPHENYLAMINO)-1,2,4-THIADIAZOL-3-YL]-PROPAN-2-OL | 2018 |
|
RU2712443C1 |
| HYDRATE OF CIPROFLOXACIN SALT WITH 4-AMINOBENZOIC ACID | 2019 |
|
RU2706351C1 |
